Arthrogen BV, Galapagos NV deal

Arthrogen and GLPG's BioFocus division (Saffron Walden, U.K.) partnered to identify gene therapy targets for rheumatoid arthritis (RA). Under the three-year deal, BioFocus will develop assays to scree...